Cargando…

Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study

INTRODUCTION: To compare the efficacy of innovator ranibizumab (iRBZ—Accentrix, Novartis, India) vs. biosimilar ranibizumab (bRBZ, Razumab-Intas, India) in eyes with diabetic macular edema (DME) in an Indian population. METHODS: Data of patients with DME who underwent at least three injections of iR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakraborty, Debdulal, Sengupta, Sabyasachi, Mondal, Soumen, Boral, Subhendu, Das, Arnab, Sinha, Tushar Kanti, Bhattacharya, Ranabir, Maitra, Ritobroto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927574/ https://www.ncbi.nlm.nih.gov/pubmed/35075621 http://dx.doi.org/10.1007/s40123-022-00463-5

Ejemplares similares

Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence
por: Chakraborty, Debdulal, et al.
Publicado: (2023)

Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Role of intravitreal brolucizumab with intravitreal rtPA and pneumatic displacement for submacular hemorrhage: A case series
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study
por: Chakraborty, Debdulal, et al.
Publicado: (2023)

A novel standardized reproducible method to calculate the area of internal limiting membrane peeled intra-operatively in macular hole surgery by using a video overlay—A long-term study in cases of idiopathic macular holes
por: Boral, Subhendu K, et al.
Publicado: (2020)

Long-term clinical outcomes of submacular blood removal with isolated autologous retinal pigment epithelium-choroid patch graft transplantation in long-standing large-sized submacular hematomas: An Indian experience
por: Boral, Subhendu Kumar, et al.
Publicado: (2020)

Commentary: To evaluate the functional and anatomical outcomes for autologous retinal autograft with Finesse™ Flex Loop for failed macular holes
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Commentary: Indistinct retinal outer layers in the walls of idiopathic full thickness macular hole - A potential predictive biomarker for surgical outcomes
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Real-world outcomes and complications of different surgical approaches for significant submacular haemorrhages
por: Boral, Subhendu Kumar, et al.
Publicado: (2023)

Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes – A multicenter retrospective study
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity
por: Prajapati, Vipul, et al.
Publicado: (2023)

Ultra-widefield image of a toxocara granuloma with an adjacent retinal break and retinal detachment
por: Chakraborty, Debdulal, et al.
Publicado: (2019)

Anatomical and functional outcomes one year after vitrectomy and retinal massage for large macular holes
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Response to comment on: Anatomical and functional outcomes one year after vitrectomy and retinal massage for large macular holes
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Response to comment on: Anatomical and functional outcomes one year after vitrectomy and retinal massage for large macular holes
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
por: Kim, Moosang, et al.
Publicado: (2013)

Critical appraisal of ranibizumab in the treatment of diabetic macular edema
por: Stewart, Michael W
Publicado: (2013)

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
por: Ratra, Dhanashree, et al.
Publicado: (2021)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema
por: Lai, Ivan Pochou, et al.
Publicado: (2020)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Commentary: Clinical profile, demographic distribution, and outcomes of ocular siderosis: Electronic medical record-driven big data analytics from an eye care network in India
por: Chakraborty, Debdulal, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Intravitreal Ranibizumab Versus Intravitreal Ranibizumab Combined with Posterior Subtenon Triamcinolone Acetonide in Diabetic Macular Edema
por: Karatas, Gamze, et al.
Publicado: (2021)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong, Angie HC, et al.
Publicado: (2013)

The macular function and structure in patients with diabetic macular edema before and after ranibizumab treatment
por: Nowacka, Barbara, et al.
Publicado: (2016)

Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
por: Bandello, Francesco, et al.
Publicado: (2011)

Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion
por: Gallego-Pinazo, Roberto, et al.
Publicado: (2012)

Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment
por: Kaya, Mahmut, et al.
Publicado: (2018)

Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema
por: Minami, Yoshiro, et al.
Publicado: (2017)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema
por: Gabr, Ahmed F., et al.
Publicado: (2023)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema
por: Goel, Siddhi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ef4cpatle4tpsmvsdv03ds4crc